双子表面活性剂 (GS) 是一类精英两亲分子，由于其卓越的理化性质，已成为药物输送领域的潜在候选者。它们由两个通过适应性间隔基和疏水尾部连接的亲水头基组成，在临床前水平向癌细胞递送不同治疗剂方面显示出有希望的结果。然而，还需要进一步的研究来释放 GS 在该领域的全部潜力。这篇综述总结了 GS 作为癌症治疗药物载体的新进展、它们克服传统缺点的能力以及疾病治疗中对创新方法的需求。本综述还提供了基于 GS 的配方的详细列表以及低聚表面活性剂的简要描述。本文总结了通过 PubMed 和 Google Scholar (2010-2023) 等文献数据库检索确定的研究数据。该领域需要解决一些重大挑战，限制了其向临床阶段的进展。进一步的研究可以集中于开发一种治疗诊断系统，该系统可以提供同步实时监测和治疗护理。然而，确保这些纳米载体的安全参数并获得监管部门的批准是一个耗时且昂贵的过程。监管机构、研究机构和制药公司之间的合作方法可以在未来几年加快这一进程。

Gemini surfactants (GS) are an elite class of amphiphilic molecules that have shown up as a potential candidate in the field of drug delivery because of their exceptional physicochemical properties. They comprise two hydrophilic headgroups connected by an adaptable spacer and hydrophobic tails that has shown promising results in delivering different therapeutic agents to cancer cells at preclinical level. However further studies are in demand to unlock the full potential of GS in this field.This review summarizes the new advancements in GS as drug carriers in cancer therapy, their capacity to overcome conventional shortcomings and the demand for innovative approaches in disease treatment. A detailed list of GS-based formulations along with a brief description on oligomeric surfactants have also been provided in this review. This article summarizes data from studies identified through literature database searches including PubMed and Google Scholar (2010-2023).There are major challenges that need to be addressed in this field which restrict their progression toward clinical phase. Further research can focus on developing a theranostic system that can provide simultaneous real-time monitoring along with treatment care. Nevertheless, ensuring the safety parameters of these nanocarriers followed by their regulatory approval is a time-consuming and expensive process. A collaborative approach between regulatory bodies, research institutions, and pharmaceutical companies can speed up the process in the upcoming years.